Tough-to-abuse formulation of oxycodone approved

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other therapies are ineffective or unavailable.

The long-acting form of oxycodone, an opioid painkiller, has properties that are designed to deter abuse of the drug by snorting or injection, the FDA said in a news release. Targiniq contains naloxone, designed to block the euphoric effects of oxycodone, the agency said.

Targiniq can still be abused by taking too many pills, the FDA warned, stressing that an overdose could cause death.

The drug is not meant for as-needed pain relief, the agency said, repeating its warning of the potential for abuse and addiction.

Targiniq ER was evaluated in a clinical study of 601 people with chronic lower back pain. The most common side effects were nausea and vomiting.

The agency said it is requiring the manufacturer to conduct additional post-marketing studies to assess the drug's risks of misuse, addiction and abuse.

Targiniq ER is manufactured by Purdue Pharma, based in Stamford, Conn.

More information: To learn more about this approval, visit the FDA.

add to favorites email to friend print save as pdf

Related Stories

FDA orders starker warnings on opioid painkillers

Sep 10, 2013

The Food and Drug Administration is requiring stronger warning labels on prescription painkillers like OxyContin, in the government's latest attempt to reduce overdose deaths caused by the long-acting medications.

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

Mar 03, 2015

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.